You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

53 search results for: mechanism of disease

UCARE 2023: Potential Role <b>of</b> Type 2 Cytokines in CSU Pathogenesis

expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

2 min

Dermatology

Dr. Saini summarises the potential role of type 2 cytokines in the pathogensis of CSU.

The Implications <b>of</b> Sweat Duct Dysfunction and the Microbial Dysbiosis in AD

expert video

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD

3 min

Dermatology

Dr. Lisa Beck talks about sweat duct dysfunction and the impact of S. aureus colonization.

The Role <b>of</b> Epithelial Barrier Components in AD: Insights and Implications

expert video

The Role of Epithelial Barrier Components in AD: Insights and Implications

6 min

Dermatology

Dr. Lisa Beck explains the role of epithelial barrier components and barrier disruption in AD.

The Role <b>of</b> Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

2 min

Dermatology

Dr. Robert Bissonnette highlights the role of type 2 inflammation in skin barrier dysfunction in atopic dermatitis.

interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

10 min

Dermatology

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

The Role <b>of</b> Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU)

Infographic

The Role of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU)

5 min

Dermatology

A summary infographic capturing how type 2 inflammation contributes to pathological processes leading to CSU signs and symptoms.

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

expert video

Exploring Neurosensitization and Pain in Prurigo Nodularis

2 min

Dermatology

Dr. Gil Yosipovitch explains that patients with PN may experience pain due to neurosensitization.

expert video

AD and PN: Commonalities and Differences – A Case Study

10 min

Dermatology

Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

expert video

Barrier Tight Junction Disruption in Atopic Dermatitis

1 min

Dermatology

Explore tight junction function in the skin and the impact of its disruption in atopic dermatitis – a soundbite from the ESDR Symposium 2022.

expert video

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

1 min

Dermatology

Dr. Kim highlights the role of non-histaminergic neuronal sensitization in CSU via cytokines.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwitzerlandChange country/region